- Announced significant expansion of our KAI Medical Laboratory in Dallas, Texas in anticipation of projected growth in COVID-19 testing requirements in the U.S., Canada and international markets.
- In addition, Empower has filed a Medical Device Establishment Licence with Health Canada for the purposes of importing, distributing and selling our KAI Medical COVID-19 Saliva Test, which has experienced immediate success since it’s launch on December 15, 2020 in the United States and reported on January 7, 2021.
VANCOUVER, BC / January 21, 2021 / EMPOWER CLINICS INC. (CSE:CBDT)(OTCQB:EPWCF)(Frankfurt:8EC) (“Empower” or the “Company“) an integrated healthcare company serving patients through clinics, a telemedicine platform, and a leading medical diagnostics laboratory processing thousands of COVID-19 specimens and developing novel COVID-19 testing protocols for CE, FDA EUA and Health Canada approval, is pleased to announce significant expansion of our KAI Medical Laboratory in Dallas, Texas in anticipation of projected growth in COVID-19 testing requirements in the U.S., Canada and international markets.
In addition, Empower has filed a Medical Device Establishment Licence (“MDEL”) with Health Canada for the purposes of importing, distributing and selling our KAI Medical COVID-19 Saliva Test (“KAI Saliva”), which has experienced immediate success since it’s launch on December 15, 2020 in the United States and reported on January 7, 2021.
KAI MEDICAL LABORATORY EXPANDING TO AT LEAST DOUBLE CURRENT SIZE IN ANTICIPATION OF ANTICIPATED GROWTH IN VOLUME
KAI Medical Laboratory, a state-of-the-art diagnostics laboratory in Dallas, was acquired by Empower Clinics on October 6, 2020 to further advance the Company’s COVID-19 national testing programs for enterprise clients, including movie and television studios, businesses and the travel industry. KAI experienced significant growth in its first quarter under Empower, with Q4 COVID-19 test kit volumes exceeding 6,000 units, far surpassing the 1,300 total units prior to acquisition.
Current run rate projections now indicate as follows:
- January 2021 is expected to exceed 8,000 tests, surpassing all of Q4 2020
- February 2021 could see daily rates hit 1,000 tests per day
- March 2021 could see daily rates hit 2,000 tests per day
These run rates DO NOT include the recent 25,000 unit order for KAI Saliva test kits, nor do they include any test kits from the launch of KAItests.com
Empower Clinics CEO, Steven McAuley stated “Our investment in R&D is really starting to pay off for KAI Medical, starting with a new state-of-art laboratory information system to automate processes for the anticipated growth in volume. Next, we have hired three new scientists, increased administrative staff and are activating a call center to provide world-class customer support. Further, the investment in new test protocols such as the Kai Saliva test kit, combined with our Health Canada medical device licence, positions us to be a leader in the reactivation of travel for Canadians.”
Read More: https://agoracom.com/ir/EmpowerClinics/forums/discussion/topics/753555-empower-clinics-doubling-kai-medical-laboratory-size-in-anticipation-of-test-volumes-by-end-of-q1-files-mdel-application-with-health-canada-to/messages/2299214#message
Tags: covid19, Covid19 testing, CSE, Diagnos Inc, investments, Kai Medical Laboratory, small cap stocks, tsx